Tian, M., Wei, J. S., Shivaprasad, N., Highfill, S. L., Gryder, B. E., Milewski, D., … Khan, J. (2024). Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell Rep Med, 5(5), 101586. https://doi.org/10.1016/j.xcrm.2024.101586

Tian, Meijie, Jun S. Wei, Nityashree Shivaprasad, Steven L. Highfill, Berkley E. Gryder, David Milewski, G Tom Brown, et al. “Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.” Cell Rep Med 5, no. 5 (May 21, 2024): 101586. https://doi.org/10.1016/j.xcrm.2024.101586.

Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, et al. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell Rep Med. 2024 May 21;5(5):101586.

Tian, Meijie, et al. “Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.” Cell Rep Med, vol. 5, no. 5, May 2024, p. 101586. Pubmed, doi:10.1016/j.xcrm.2024.101586.

Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou H-C, Song YK, Rahmy A, Masih KE, Kim YY, Belyea B, Linardic CM, Dropulic B, Sullivan PM, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL, Orentas RJ, Cheuk AT, Khan J. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell Rep Med. 2024 May 21;5(5):101586.